Article

LADAR 6000: good but time consuming

Although the LADAR 6000 (Alcon) is accurate and safe, the need for pharmacological mydriasis and the use of a nomogram result in a more time consuming surgical procedure.

Although the LADAR 6000 (Alcon) is accurate and safe, the need for pharmacological mydriasis and the use of a nomogram result in a more time consuming surgical procedure, according to Joaquim Murta and colleagues from Coimbra University, Portugal.

A total of 300 consecutive eyes underwent refractive surgery with the LADAR 6000. Of those, 245 were submitted to photorefractive keratectomy (PRK) to correct a manifest spheroequivalent refractive error (MSRE) of -5.5+4.3 D, with a cylinder ranging from -4.50 to +3.50 D. Fifty-five eyes were submitted to LASIK using the Zyoptix XP microkeratome (Bausch & Lomb) to correct MSRE of -0.75 to -9.29 with a cylinder ranging from 0.00 to -5.50 D.

Following PRK, uncorrected visual acuity (UCVA) was 0.9, best spectacle corrected visual acuity (BSCVA) was 1.0 and MSRE was 0.00. The eyes which underwent LASIK reached a UCVA of 0.7, a BSCVA of 0.9 and a MSRE of 0.4. Just one eye lost two lines of BSCVA due to adenoviral keratoconjunctivitis.

Dr Murta concluded that the LADAR 6000 offers good results but is a time consuming procedure.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.